Mikael Orum
Founder of Ventac Partners
Mikael Orum
Founder of Ventac Partners
Copenhagen, Capital Region of Denmark
Overview
Work Experience
Chairman of the Board of Directors
2023 - Current
Qmed Consulting is a full Service Clinical Research Organisation (CRO) specialised in Medical Devices managing Clinical Trials and conducting Strategic Consultancy within Regulatory Affairs, Quality Assurance and Market Access and Reimbursement.
Chairman of the Board of Directors
2022
Next Generation Neuromodulation Solutions and Beyond
Advisory Board Member
2021
Cube Labs is a publicly listed venture company enabling innovation in the healthcare technology space. Cube Labs builds companies from promising early-stage R&D, and provide entrepreneurial and operational support at all the stages of their life cycle to transform pioneering science into healthcare solutions.
Board Member
2021
IXALTIS is a therapeutic company specialized in genitourinary and renal diseases. IXALTIS has acquired the rights to three molecules from Sanofi, including its lead compound Litoxetine (IXA-001), and completed a round A of financing in 2016
Founder & Partner
2002
Has built the organization from ground up. Today counting 18 partners, representing a multi- disciplinary executive team, with offices coast-to-coast in USA, and in key biotech centers in Europe and Shanghai, China. Exploiting its international network and in-house capabilities, Ventac Partners are international experts in identifying groundbreaking discoveries and innovations within the areas of pharma and diagnostics. Due to its international reach, the organization has built a portfolio in excess of ten companies in key centers in the US and Europe. The Organization provides strategic and operational advice and resources to life science companies. This includes equity capital raise, in- & out-licensing services, M&A, IPO/RTO and other transactional services.
Chairman Of The Board Of Directors
2016
Orbit Genomics is a privately held diagnostic startup company domiciled in Boulder, Colorado. It builds its product platform on pioneering R&D within the field of genomics DNA. First product in development is against lung cancer. Orbit Genomics is currently in collaboration with several companies and academic groups analyzing additional novel product opportunities based on the platform.
Chairman of the Board of Directors
2010 - 2020
Neuroscience Technologies (dissolved in 2020) was a privately held specialty service provider to the pharmaceutical and biotech industries within human pain neurophysiology. The company was based on a unique expertise in pre-clinical and clinical space employing its proprietary technology platform enabling neurophysiological assessment of the peripheral and central nociceptive pathways. As Chair, has led the strategic turn-around of the company. Business was discontinued in 2020 as a result of the covid-19 pandemic.
Chairman of the Board of Directors
2014 - 2019
RhoVac is originally a Danish biotech company developing a therapeutic vaccine against metastatic cancer. As Chair, led a private placement in RhoVac and subsequently took the company to the Swedish capital market through the incorporation of a Swedish holding company and listed the company on Spotlight, a growth capital stock exchange in Sweden. Subsequent to listing, RhoVac has completed a successful first-dose-in-man and is currently completing a phase II study. Company has raised approx. US$ 28 million in equity and soft funding.
Chairman & CEO
2005 - 2019
Coegin Pharma is a publicly traded therapeutic company focused in the space of chronic inflammation and cancer. Coegin Pharma has developed a pipeline of clinical and non-clinical stage novel small molecules. As CEO, has built the company from ground up. Company has raised approx. US$ 23 million in equity and non-dilutive funding under my leadership.
Chairman of the Board of Directors
2017 - 2018
Amunix is a privately held platform company in the discovery and development of long-acting protein- based therapeutics and drug conjugation technologies. Exploiting its drug platforms, Amunix is actively engaged in both a diverse array of internal product development efforts as well as under ongoing licenses with pharma companies. As Chair, represented the majority shareholder staging a turn-around of the company with the objective to streamline the company for venture funding/partnering/M&A. During the period, the company concluded several licenses and R&D agreements with large pharma. The Board re-prioritized existing drug development projects and updated the overall business plan for the company. Furthermore, the Board conducted a full audit of the company, and prepared for the hiring of a new CEO. Majority stock sold to a large US Venture Capital firm. The company is now preparing for an IPO on Nasdaq, USA.